Brief: Hofseth Biocare: Preclinical Research With OmeGo Demonstrates Potential To Treat Eosinophilic Asthma

Hofseth Biocare ASA

15/05/2020 08:45

May 15 (Reuters) - Hofseth Biocare ASA  HOFBC.OL :
    * REG-HOFSETH BIOCARE ASA: PRECLINICAL RESEARCH WITH OMEGO®
DEMONSTRATES POTENTIAL TO TREAT EOSINOPHILIC ASTHMA
    * OMEGO® CONTAINS MINOR LIPID-SOLUBLE COMPONENTS THAT HAVE
BEEN
SHOWN TO REDUCE EOSINOPHIL EFFECTOR FUNCTION (EEF) AND INCREASE
EOSINOPHIL APOPTOSIS (PROGRAMMED CELL DEATH) IN VARIOUS INVITRO
CELLULAR ASSAYS AT 100 UG/ML CONCENTRATIONS.
    * WE WILL CONTINUE TO DEVELOP THIS INDICATION BY PROGRESSING
TOWARDS PRE-CLINICAL ANIMAL TRIALS IN Q3 2020,
    * WE ANTICIPATE THAT THIS WILL LEAD TO INITIATION OF PHASE 1
CLINICAL TRIAL WORK IN ASTHMA DURING 2021

Source text for Eikon:  ID:nGNE7J6rb6 
Further company coverage:  HOFBC.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))